Neuropace Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuropace, Inc. on April 13, 2023, covering events occurring on April 11, 2023. The company is incorporated in Delaware and its common stock trades on the Nasdaq Global Market under the symbol NPCE.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On April 11, 2023, Greg Garfield notified the company that he will not stand for reelection as a director to the Board of Directors. The filing states this decision was not due to any disagreements with the company regarding its operations, policies, or practices. Consequently, the Board intends to reduce its size from eight to seven directors, effective as of the Annual Meeting.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the specific event of the director's departure.
Key Facts for Investors to Verify
- Greg Garfield will not seek reelection as a director.
- The Board size will be reduced from eight to seven members.
- The departure is not attributed to any disagreement with company management or policy.
- The change in Board composition will take effect at the Annual Meeting.